FDA Seeks Comments on Minor Animal Drug Data Collection
Published Date: 6/29/2026
Notice
Summary
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
7-Year Marketing Exclusivity Incentive
If you obtain a MUMS (Minor Use/Minor Species) drug designation, you become eligible for incentives under sections 572 and 573 of the FD&C Act, including a 7-year period of exclusive marketing rights for the designated use. The designation is optional and requires sponsors to apply and demonstrate due diligence through annual reports.
Annual Reporting and Recordkeeping Burden
If you are a company that sponsors new animal drugs for minor uses or minor species, you must submit reports and keep records under 21 CFR part 516. FDA estimates the total annual reporting burden is 5,562 hours and the annual recordkeeping burden is 80 hours across respondents; these cover specific activities (for example, 516.30 annual reports and 516.165 drug experience reports).
Guidance and Small Business Resources Provided
FDA acknowledges concerns about administrative and financial burdens on smaller companies and points to resources to help them, including the FDA Small Business Guide and Guidance for Industry documents (CVM GFI #61, #170, #200, #201) and a planned revision of CVM GFI #210. These materials are intended to help sponsors navigate designation and indexing processes.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
Previous / Next Documents
Previous: 2026-13004, NextEra Energy Duane Arnold, LLC; Establishment of Atomic Safety and Licensing Board
NextEra Energy wants to update its license to keep the Duane Arnold Energy Center in Iowa running. Because a group called Physicians for Social Responsibility Iowa asked for a hearing, a special board of judges is now set up to review the request. This process will decide if the plant can continue operating, affecting local energy and safety rules soon.
Next: 2026-13006, Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.